Clinical trials recruiting for Hormone Sensitive Prostate Cancer
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 2 |
| Alabama | 1 |
| Arizona | 1 |
| Arkansas | 1 |
| California | 1 |
| Colorado | 1 |
| Georgia | 1 |
| Illinois | 1 |
| Michigan | 1 |
| New Jersey | 1 |
| New York | 1 |
| North Carolina | 1 |
Top cities
Self-screener
Recruiting trials
- Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
- Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
- Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
- PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Related conditions
Trials recruiting for Hormone Sensitive Prostate Cancer often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Hormone Sensitive Prostate Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.